USANA Beats Expectations, Shares Surge

USANA Health Sciences surpasses expectations with Q1 2026 results, reporting $250 million in sales and $0.61 in adjusted EPS, beating analyst predictions by 3.7% and 39.1% respectively. The company maintains its full-year outlook, with revenue guidance at $962.5 million and EPS at $2.12. Despite slower growth and average cash flow, analysts anticipate 3.3% revenue growth over the next year, driven by new products. Shares rise 2.9% to $19.80 post-earnings, suggesting potential upside but emphasizing the importance of long-term quality and valuation. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fff8b47b1c5bbc21